AVEO Oncology in Collaboration, Supply Agreement With Eli Lilly
June 22 2022 - 8:49AM
Dow Jones News
By Chris Wack
AVEO Oncology Inc. said it has entered into a clinical trial
collaboration and supply agreement in North America with Eli Lilly
& Co. to evaluate ficlatuzumab in combination with Erbitux
cetuximab in patients with recurrent or metastatic head and neck
squamous cell carcinoma.
Under the terms of the agreement, Lilly will provide cetuximab
clinical drug supply in the U.S. and Canada for AVEO's potential
registrational study, which will assess ficlatuzumab with cetuximab
in HPV negative recurrent or metastatic head and neck squamous cell
carcinoma, AVEO said. AVEO will serve as the study sponsor and will
be responsible for trial execution.
Ficlatuzumab is AVEO's investigational potent humanized
immunoglobulin G1 monoclonal antibody that targets hepatocyte
growth factor.
AVEO began manufacturing ficlatuzumab clinical supply in the
second quarter of 2022, and the potential registrational study is
expected to be initiated in the first half of 2023, it said.
AVEO said it expects to continue to discuss potential
ficlatuzumab pivotal study designs with the FDA and to continue
ongoing partnership dialogues.
AVEO shares were up 3% to $4.95 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 22, 2022 08:34 ET (12:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024